Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis

References

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Gadina M, and Siegel R, et al. 2018. Rheumatology: cytokine. 7th ed. Philadelphia, PA: Elsevier; 86–100.
   Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–170.
   PubMed Web of Science ®Google Scholar
• Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci. 2004;25:201–209.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.
   PubMed Web of Science ®Google Scholar
• Shuai K, Stark GR, lM K, et al. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science. 1993;261:1744–1746.
   PubMed Web of Science ®Google Scholar
• Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019;58:i4–i16.
   PubMed Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci. 1994;19:222–227.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:1603–1607.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Gadina M, O’Shea JJ, et al. SnapShot: Jak-STAT signaling II. Cell. 2020;181:1696.e1.
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270:797–800.
   PubMed Web of Science ®Google Scholar
• Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212:1641–1662.
   PubMed Web of Science ®Google Scholar
• Hainzl E, Stockinger S, Rauch I, et al. Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis. J Immunol. 2015;195:5011–5024.
   PubMed Web of Science ®Google Scholar
• Eletto D, Burns SO, Angulo I, et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat Commun. 2016;7:13992.
   PubMed Web of Science ®Google Scholar
• Gruber CN, Calis JJA, Buta S, et al. Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function. Immunity. 2020;53:672–84.e11.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Tao JH, Zou YF, Feng XL, et al. Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol Biol Rep. 2011;38:4663–4672.
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–878.
   PubMed Web of Science ®Google Scholar
• Walsh PT, Strom TB, Turka LA. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity. 2004;20:121–131.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
   PubMed Web of Science ®Google Scholar
• Gadina M, Chisolm DA, Philips RL, et al. Translating JAKs to Jakinibs. J Immunol. 2020;204:2011–2020.[**extensive and updated review of the literature on JAK-STAT pathway, from the discovery to the therapeutic targeting in the treatment of inflammatory diseases].
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Meylan F, O’Shea JJ, et al. JAK inhibitors: ten years after. Eur J Immunol. 2021;51:1615–1627.
   PubMed Web of Science ®Google Scholar
• Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35:939–951.
   PubMed Web of Science ®Google Scholar
• Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013;191:2205–2216.
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–3577.
   PubMed Web of Science ®Google Scholar
• Menet CJ, Fletcher SR, Van Lommen G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014;57:9323–9342.
   PubMed Web of Science ®Google Scholar
• Voss J, Graff C, Schwartz A, et al. THU0127 pharmacodynamics of a novel JAK1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Ann Rheum Dis. 2014;73:222.
   Google Scholar
• Graff C, Schwartz A, and Voss J, et al. Characterization of ABT-494, a second generation Jak1 selective inhibitor. Ab number 1499. Arthritis Rheum. 2014;Suppl 10:S659.
   Google Scholar
• Bechman K, Yates M, Galloway JB. The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors. Pharmacol Res. 2019;147:104392.
   PubMed Web of Science ®Google Scholar
• Cox L, Cools J. JAK3 specific kinase inhibitors: when specificity is not enough. Chem Biol. 2011;18:277–278.
   PubMedGoogle Scholar
• Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol. 2011;18:314–323.
   PubMed Web of Science ®Google Scholar
• Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7:e00537.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21:183.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:41.
   Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:1–11.
   PubMedGoogle Scholar
• Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–875.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790–1798.
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192–2198.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Sakata K, et al. janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9:1510.
   PubMed Web of Science ®Google Scholar
• Reddig A, Voss L, Guttek K, et al. Impact of different JAK inhibitors and methotrexate on lymphocyte proliferation and DNA damage. J Clin Med. 2021;10:1431.
   PubMed Web of Science ®Google Scholar
• Piscianz E, Valencic E, Cuzzoni E, et al. Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One. 2014;9:e85463.
   PubMed Web of Science ®Google Scholar
• Brusko TM, Wasserfall CH, Hulme MA, et al. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One. 2009;4:e7980.
   PubMed Web of Science ®Google Scholar
• Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58:2051–2060.
   PubMed Web of Science ®Google Scholar
• Isailovic N, Ceribelli A, Cincinelli G, et al. Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis. Clin Exp Immunol. 2021;205:142–149.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–4243.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, McInnes IB, Taylor PC, et al. Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheumatol. 2018;70:1923–1932.
   PubMed Web of Science ®Google Scholar
• Meyer A, Wittekind PS, Kotschenreuther K, et al. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. Ann Rheum Dis. 2021;80:e196.
   PubMed Web of Science ®Google Scholar
• Wang SP, Iwata S, Nakayamada S, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213–2215.
   PubMed Web of Science ®Google Scholar
• Martina MN, Ramirez Bajo MJ, Bañon-Maneus E, et al. Inhibition of JAK3 and PKC via immunosuppressive drugs tofacitinib and sotrastaurin inhibits proliferation of human B lymphocytes In Vitro. Transplant Proc. 2016;48:3046–3052.
   PubMed Web of Science ®Google Scholar
• Rizzi M, Lorenzetti R, Fischer K, et al. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun. 2017;77:55–66.
   PubMed Web of Science ®Google Scholar
• Furuya MY, Asano T, Sumichika Y, et al. Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Res Ther. 2018;20:196.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Matsuoka N, Temmoku J, et al. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. BMC Immunol. 2020;21:35.
   PubMed Web of Science ®Google Scholar
• Mitchell TS, Moots RJ, Wright HL. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production. Clin Exp Immunol. 2017;189:250–258.
   PubMed Web of Science ®Google Scholar
• Stalder R, Zhang B, Jean Wrobel L, et al. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. Exp Dermatol. 2020;29:71–78.
   PubMed Web of Science ®Google Scholar
• Wenink MH, Santegoets KC, Butcher J, et al. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis Rheum. 2011;63:3313–3322.
   PubMedGoogle Scholar
• Magnol M, Rauwel B, Sayegh S, et al. AB0040 Jak inhibitors – baricitinib and tofacitinib – modulate the in vitro inflammatory and alternative polarizations of macrophages. Ann Rheum Dis. 2019;78:1486–1487.
   Web of Science ®Google Scholar
• Lescoat A, Lelong M, Jeljeli M, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103.
   PubMed Web of Science ®Google Scholar
• Ikari Y, Isozaki T, Tsubokura Y, et al. Peficitinib inhibits the chemotactic activity of monocytes via proinflammatory cytokine production in rheumatoid arthritis fibroblast-like synoviocytes. Cells. 2019;8:561.
   PubMed Web of Science ®Google Scholar
• Yang X, Wan M, Cheng Z, et al. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artif Cells Nanomed Biotechnol. 2019;47:2775–2782.
   PubMed Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12:3391.
   PubMed Web of Science ®Google Scholar
• Vian L, Le MT, Gazaniga N, et al. JAK inhibition differentially affects NK cell and ILC1 homeostasis. Front Immunol. 2019;10:2972.
   PubMed Web of Science ®Google Scholar
• Nocturne G, Pascaud J, Ly B, et al. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis. Cell Mol Immunol. 2020;17:552–553.
   PubMed Web of Science ®Google Scholar
• Klein K, Stoiber D, and Sexl V, et al. Untwining anti-tumor and Immunosuppressive effects of JAK inhibitors-A strategy for hematological malignancies? Cancers (Basel). 2021;13:2611.
   PubMed Web of Science ®Google Scholar
• Robinette ML, Cella M, Telliez JB, et al. Jak3 deficiency blocks innate lymphoid cell development. Mucosal Immunol. 2018;11:50–60.
   PubMed Web of Science ®Google Scholar
• Overstreet AM, LaTorre DL, Abernathy-Close L, et al. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 2018;11:1454–1465.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the Short-, Mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:685–695.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.
   PubMed Web of Science ®Google Scholar
• Weinhold KJ, Bukowski JF, Brennan TV, et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol. 2018;191:10–20.
   PubMed Web of Science ®Google Scholar
• Sonomoto K, Yamaoka K, Kubo S, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford). 2014;53:914–918.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017;56:46–57.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther. 2020;22:47.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68:2857–2866.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69:932–942.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69:709–719.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43:504–511.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–1252.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88–95.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Emery P, Camp HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68:2867–2877.
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80:304–311.
   PubMed Web of Science ®Google Scholar
• Tarrant JM, Galien R, Li W, et al. Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials. Rheumatol Ther. 2020;7:173–190.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or Adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–858.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315–325.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727–738.
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Colbert RA, Gadina M. JAK1: number one in the family; number one in inflammation? Rheumatology (Oxford). 2021;60(Suppl 2):ii3–ii10.
   PubMedGoogle Scholar
• Nash P, Kerschbaumer A, Dorner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71–87.
   PubMed Web of Science ®Google Scholar
• Goodman SM, Springer B, Guyatt G, et al. American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69:1538–1551.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, and Mikuls TRet al, Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316–326.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Pawar A, Khosrow-Khavar F, et al. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021;61:121–130.
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, and Kim SC, Lee H et al Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022. annrheumdis-2021-221915.
   PubMedGoogle Scholar